Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$450K Buy
5,218
+1,639
+46% +$136K 0.07% 65
2026
Q2
$241K Buy
+3,579
New +$238K 0.04% 100
2020
Q4
– Sell
-112,236
Closed -$11.6M – 93
2020
Q3
$11.6M Buy
112,236
+4,616
+4% +$482K 4.18% 6
2020
Q2
$10.9M Buy
107,620
+22,652
+27% +$2.03M 4.47% 5
2020
Q1
$7.12M Buy
84,968
+40,064
+89% +$2.49M 3.27% 14
2019
Q4
$2.46M Buy
44,904
+2,804
+7% +$133K 1.01% 33
2019
Q3
$1.57M Buy
+42,100
New +$1.64M 0.69% 38

Other funds holding DXCM

Beck Bode's DXCM Position: Q3 2026 in Review

Beck Bode increased its DexCom (DXCM) stake by 46% in Q3 2026, buying an estimated $136K and bringing the position to 5,218 shares worth $450K. The position accounts for 0.07% of the portfolio, ranked #65.

Beck Bode first reported a position in DXCM in Q3 2019 and has held it in 7 quarters since. The position peaked at $11.6M in Q3 2020. 863 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Beck Bode held 5,218 shares of DexCom worth $450K as of Q3 2026.
  • Beck Bode bought 1,639 DexCom shares in Q3 2026, an estimated $136K.
  • DexCom made up 0.07% of Beck Bode's portfolio in Q3 2026, its #65 holding.
  • Beck Bode first reported a position in DexCom in Q3 2019 and has held it in 7 quarters since.
  • Beck Bode's DexCom position peaked at $11.6M in Q3 2020.
  • 863 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Beck Bode's 13F filing for Q3 2026, filed 12 Nov 2026.